GlassScriptPhysician profile
Mark T Nguyen
NPI 1427348150
$677.45
in general payments reported to CMS, 2019-2025
13 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2021: $40.82 · 2022: $47.10 · 2023: $22.71 · 2024: $109 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.71 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $133.62 | 2019-2022 | |
| Shire North American Group INC | $121.80 | 2019 | |
| Nxstage Medical, INC. | $72.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.00 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $58.27 | 2024 | Jynarque |
| Scpharmaceuticals INC. | $41.64 | 2025 | |
| Aurinia Pharma U.S., INC. | $40.82 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.04 | 2023-2025 | Jardiance |
| Veloxis Pharmaceuticals, INC. | $31.46 | 2025 | Envarsus |
| Astrazeneca Pharmaceuticals LP | $27.64 | 2022 | |
| Glaxosmithkline, LLC. | $17.89 | 2025 | Arexvy, Shingrix |
| Travere Therapeutics, INC. | $17.62 | 2022-2024 | |
| Cormedix INC. | $14.05 | 2025 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.